Detail akcie Lipocine Rg online

Business Summary: Lipocine Inc. is a biopharmaceutical company leveraging its proprietary technology platform to enable effective oral delivery of therapeutics. The Company’s clinical development candidates include: LPCN 1154, oral brexanolone, for the treatment of postpartum depression, LPCN 2101, for the treatment of epilepsy, LPCN 2203, an oral candidate targeted for the management of essential tremor, LPCN 2401, an oral proprietary anabolic androgen receptor agonist for improved body composition in obesity management, and LPCN 1148, for the management of decompensated cirrhosis. It is also developing LPCN 1107, for the prevention of preterm birth, LPCN 1154, for rapid relief of postpartum depression, and LPCN 1144, for the treatment of metabolic dysfunction-associated steatohepatitis. Its product candidate, TLANDO, is a novel oral prodrug of testosterone containing testosterone undecanoate developed by the Company.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Lipocine Inc revenues decreased 89% to $831K. Net loss increased from $1.8M to $7.3M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development for the delivery of drugs using its segment loss increase of 33% to $7.9M.